New Directions in Iron Chelating Therapy

摘要: Although the iron chelating drug deferroxamine has been available for clinical use over three decades, it only gained acceptance as a useful therapeutic agent in late seventies following demonstration of its ability to deplete excess stores thalassemic patients. Recognition central role generation toxic, oxygen-derived species through Haber-Weiss reaction (1), documentation deferoxamine (DF) prevent damage associated with free radical reperfusion injury, and inhibit proliferation malignant cells protozoa such malarial parasite by inactivation iron-dependent enzyme ribonucleotide reductase, resulted large number studies exploring novel applications drugs. Some information this field reviewed previous publications (2). The purpose present chapter is summarize state art DF other selective chelators conditions unrelated overload.